Startup
Programs: CUREator
Every investor coverage indicates participated in a round Phrenix raised.
Companies Phrenix acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Professor Chris Langmead | Chief Executive (former) | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Phrenix. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech incubator CUREator has awarded its first grants, totalling $17.4 million, to 23 early-stage medical startups including Phrenix and RAGE Biotech, aiming to ready them for commercial investment.